Hasil Pencarian (17430)
Halaman 311 / 349Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections.…
Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).
Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)).
Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).
Sus scrofa placenta is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare blee…
Sutetinib is under investigation in clinical trial NCT05168566 (Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Sutezolid has been used in trials studying the treatment of Tuberculosis.
Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cr…
Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15…
Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).
SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects).
Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Deskripsi belum tersedia.
Suzetrigine is under investigation in clinical trial NCT05558410 (Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty).
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neur…
Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
SX-682 is under investigation in clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp Alfa (M7824 or Tgf-beta "Trap"/pd-l1) With CV301 TRIC…
Deskripsi belum tersedia.
Deskripsi belum tersedia.
SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer. SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells.
SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 20…
SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug.[A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is desig…
SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.[A256733] SYNB1891 is under investigation in clinical trial NCT0416713…
Synephrine, also referred to as, p-synephrine, is naturally occurring alkaloid. It is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to…
SynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor …
Synthetic conjugated estrogens A are composed of a blend of the following nine synthetic estrogenic substances: estrone sulfate, sodium equilin sulfate, sodium 17?-dihydroequilin sulfate, sodium 17?-estradiol sulfate, sodium 17? dihydroequilin sulfate, sodiu…
Synthetic conjugated estrogens, B tablets contain a blend of ten synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17?-dihydroequilin sulfate, sodium 17?-estradiol sulfate, sodium 17? dihyd…
T2000 has been used in trials studying the treatment of Myoclonus and Essential Tremor.
T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.
T-62 has been used in trials studying the treatment of Postherpetic Neuralgia.
T900607 has been used in trials studying the treatment of Liver Cancer and Gastric Cancer.